Skip to main content

Table 1 Baseline characteristics

From: Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial

  Fibrinogen concentrate arm Placebo arm
Subjects
 No. 24 24
 Age, yr 38 (31–47) 36 (22–56)
 Male, n (%) 20 (83) 19 (79)
Timelines
 Injury to hospitala, min 98 (77–118) 87 (66–116)
Injuries and admission physiologic measures
 Blunt 21 (88) 18 (75)
 ISS 34 (24–43) 29 (22–34)
 Systolic blood pressure, mmHg 86 (72–124) 95 (82–128)
 Heart rate, beats/min 101 (88–116) 112 (93–126)
 GCS 3 (3–14) 3 (3–15)
 Clauss fibrinogen level, g/L 1.9 (0.9–2.2) 2.3 (1.6–2.5)
 EXTEM CA5 26 (15–28) 35 (26–42)
 FIBTEM CA5 4 (3–7) 7 (4–12)
Pre-randomisation
 TXA administered pre-admission 18 (75) 20 (83)
 RBC, units 1 (0–2) 1 (0–2)
 FFP, units 0 (0–1) 0 (0–2)
 Crystalloids, ml 0 (0–475) 0 (0–625)
  1. Abbreviations: CA5 Clot amplitude at 5 min, FFP Fresh frozen plasma, GCS Glasgow Coma Scale, ISS Injury Severity Score, RBC Red blood cells, TXA Tranexamic acid
  2. Data are number (%) for categorical variables and median (IQR) for continuous variables
  3. aOne participant was admitted to hospital > 3 h after injury (subsequently defined as a protocol deviation)